CA2382886A1 - Benzamide formulation with histone deacetylase inhibitor activity - Google Patents
Benzamide formulation with histone deacetylase inhibitor activity Download PDFInfo
- Publication number
- CA2382886A1 CA2382886A1 CA002382886A CA2382886A CA2382886A1 CA 2382886 A1 CA2382886 A1 CA 2382886A1 CA 002382886 A CA002382886 A CA 002382886A CA 2382886 A CA2382886 A CA 2382886A CA 2382886 A1 CA2382886 A1 CA 2382886A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- histone deacetylase
- benzamide
- injections
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
There are provided pharmaceutical formulations with improved oral absorptivity and injections that contain, as active ingredients, high concentrations of benzamide derivatives and their pharmaceutically acceptable salts, which are useful as histone deacetylase inhibitors. A pharmaceutical solution is prepared by dissolving a benzamide derivative or a pharmaceutically acceptable salt thereof in an organic solvent and/or acidic liquid, and a pharmaceutical formulation is prepared by adding a surfactant, an acidic substance and/or a polyethylene glycol. The present invention has enabled dissolution of benzamide derivatives or their pharmaceutically acceptable salts at high concentrations, to prepare practical injections and oral liquid formulations and improve absorptivity with oral administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/242444 | 1999-08-30 | ||
JP24244499A JP2001081031A (en) | 1999-08-30 | 1999-08-30 | Benzamide derivative-containing preparation having improved solubility and oral adsorption |
PCT/EP2000/008421 WO2001016106A1 (en) | 1999-08-30 | 2000-08-29 | Benzamide formulation with histone deacetylase inhibitor activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2382886A1 true CA2382886A1 (en) | 2001-03-08 |
CA2382886C CA2382886C (en) | 2009-06-09 |
Family
ID=17089193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002382886A Expired - Fee Related CA2382886C (en) | 1999-08-30 | 2000-08-29 | Benzamide formulation with histone deacetylase inhibitor activity |
Country Status (32)
Country | Link |
---|---|
US (1) | US6638530B1 (en) |
EP (1) | EP1208086B1 (en) |
JP (2) | JP2001081031A (en) |
KR (1) | KR100712640B1 (en) |
CN (1) | CN1147472C (en) |
AR (1) | AR025434A1 (en) |
AT (1) | ATE318258T1 (en) |
AU (1) | AU773617B2 (en) |
BG (1) | BG65544B1 (en) |
BR (1) | BR0013648A (en) |
CA (1) | CA2382886C (en) |
CZ (1) | CZ301737B6 (en) |
DE (1) | DE60026144T2 (en) |
DK (1) | DK1208086T3 (en) |
EE (1) | EE05063B1 (en) |
ES (1) | ES2259289T3 (en) |
HK (1) | HK1046277B (en) |
HR (1) | HRP20020182B1 (en) |
HU (1) | HUP0203330A3 (en) |
IL (2) | IL148357A0 (en) |
MX (1) | MXPA02002090A (en) |
NO (1) | NO322532B1 (en) |
NZ (1) | NZ517520A (en) |
PL (1) | PL201274B1 (en) |
PT (1) | PT1208086E (en) |
RU (1) | RU2260428C2 (en) |
SI (1) | SI1208086T1 (en) |
SK (1) | SK287252B6 (en) |
TW (1) | TWI268778B (en) |
UA (1) | UA72541C2 (en) |
WO (1) | WO2001016106A1 (en) |
ZA (1) | ZA200201424B (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
EP1374855A1 (en) * | 2001-03-30 | 2004-01-02 | Takeda Chemical Industries, Ltd. | Medicinal solutions |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
AU2006252047B2 (en) * | 2001-09-14 | 2010-02-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
KR20040048411A (en) * | 2001-09-14 | 2004-06-09 | 메틸진, 인크. | Inhibitors of histone deacetylase |
US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
EP2269609A3 (en) | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
WO2003070691A1 (en) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
RU2320331C2 (en) | 2002-03-04 | 2008-03-27 | МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. | Method of induction of terminal differentiation |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
AU2003220119A1 (en) | 2002-03-07 | 2003-09-22 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
DE10233412A1 (en) * | 2002-07-23 | 2004-02-12 | 4Sc Ag | New compounds as histone deacetylase inhibitors |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
GB0226855D0 (en) * | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
US7244751B2 (en) * | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
JP2006520796A (en) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
CN100455564C (en) * | 2003-09-12 | 2009-01-28 | 深圳微芯生物科技有限责任公司 | Histone de-acetylase inhibitor, preparation and application of pharmaceutical preparations of the same |
CN101445469B (en) * | 2003-09-24 | 2013-02-13 | 梅特希尔基因公司 | Inhibitors of histone deacetylase |
EP1663953A1 (en) * | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
JP5107579B2 (en) | 2003-12-02 | 2012-12-26 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | Zn2 + chelate motif tethered short chain fatty acids as a novel class of histone deacetylase inhibitors |
EP1697538A1 (en) * | 2003-12-18 | 2006-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Method for identifying histone deacetylase inhibitors |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7604939B2 (en) * | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
WO2006122319A2 (en) | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
WO2007011626A2 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2007017728A2 (en) * | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
CA2648594C (en) * | 2006-04-07 | 2012-10-16 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
ES2452820T3 (en) | 2006-04-07 | 2014-04-02 | Methylgene, Inc. | Benzamide derivatives as histone deacetylase inhibitors |
US20070292512A1 (en) * | 2006-06-09 | 2007-12-20 | Merrion Research Ii Limited | Solid Oral Dosage Form Containing an Enhancer |
US20100056522A1 (en) | 2007-03-28 | 2010-03-04 | Santen Pharmaceutical Co., Ltd. | Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient |
US20110044952A1 (en) * | 2007-11-27 | 2011-02-24 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
WO2009126662A1 (en) * | 2008-04-08 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator |
US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
JP2011520891A (en) * | 2008-05-16 | 2011-07-21 | チップスクリーン バイオサイエンシーズ エルティーディー. | 6-Aminonicotinamide derivatives as potent and selective histone deacetylase inhibitors |
US8623853B2 (en) | 2008-07-23 | 2014-01-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancers characterized by chromosomal rearrangement of the NUT gene |
TWI480286B (en) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | Composition and drug delivery of bisphosphonates |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
CN103172540B (en) * | 2013-03-18 | 2015-07-01 | 潍坊博创国际生物医药研究院 | Phenylglycine histone deacetylase inhibitor as well as preparation method and applications thereof |
WO2015051035A1 (en) | 2013-10-01 | 2015-04-09 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
JP7211704B2 (en) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | A tablet containing a GLP-1 agonist and an enteric coating |
EP3317281B1 (en) | 2015-07-02 | 2020-04-22 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
US20190224146A1 (en) * | 2016-07-08 | 2019-07-25 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases |
WO2018222572A1 (en) * | 2017-06-01 | 2018-12-06 | Warner Babcock Institute For Green Chemistry, Llc | Non-covalent derivatives and methods of treatment |
WO2018226939A1 (en) * | 2017-06-07 | 2018-12-13 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing cancer |
EP3960240B1 (en) | 2019-04-25 | 2024-03-27 | Fuji Pharma Co., Ltd. | Pharmaceutical preparation and method for producing same |
CN112294810B (en) * | 2019-07-29 | 2024-03-01 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing cetadalimamine and surfactant |
CA3199945A1 (en) | 2020-10-28 | 2022-05-05 | Kinopharma, Inc. | Pharmaceutical composition for preventing or treating viral perivaginal disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0956865T2 (en) * | 1996-08-12 | 2011-04-29 | Mitsubishi Pharma Corp | MEDICINES COMPRISING Rho KINASE INHIBITOR |
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
JP3354090B2 (en) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | Differentiation inducer |
JP4405602B2 (en) * | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Histone deacetylase inhibitor |
JP2000256194A (en) * | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | Intranuclear receptor agonist and agent for enhancing its effect |
JP2001064177A (en) * | 1999-08-16 | 2001-03-13 | Schering Ag | Pharmaceutical preparation including benzamide derivative as ingredient |
-
1999
- 1999-08-30 JP JP24244499A patent/JP2001081031A/en active Pending
-
2000
- 2000-08-29 JP JP2001519675A patent/JP2003508386A/en not_active Withdrawn
- 2000-08-29 IL IL14835700A patent/IL148357A0/en active IP Right Grant
- 2000-08-29 CN CNB008122849A patent/CN1147472C/en not_active Expired - Fee Related
- 2000-08-29 CZ CZ20020724A patent/CZ301737B6/en not_active IP Right Cessation
- 2000-08-29 AR ARP000104493A patent/AR025434A1/en unknown
- 2000-08-29 DE DE60026144T patent/DE60026144T2/en not_active Expired - Lifetime
- 2000-08-29 HU HU0203330A patent/HUP0203330A3/en unknown
- 2000-08-29 KR KR1020027002163A patent/KR100712640B1/en not_active IP Right Cessation
- 2000-08-29 PL PL353063A patent/PL201274B1/en not_active IP Right Cessation
- 2000-08-29 RU RU2002107992/15A patent/RU2260428C2/en active IP Right Revival
- 2000-08-29 MX MXPA02002090A patent/MXPA02002090A/en active IP Right Grant
- 2000-08-29 AU AU68416/00A patent/AU773617B2/en not_active Ceased
- 2000-08-29 TW TW089117485A patent/TWI268778B/en not_active IP Right Cessation
- 2000-08-29 US US10/069,582 patent/US6638530B1/en not_active Expired - Fee Related
- 2000-08-29 NZ NZ517520A patent/NZ517520A/en not_active IP Right Cessation
- 2000-08-29 SK SK261-2002A patent/SK287252B6/en not_active IP Right Cessation
- 2000-08-29 AT AT00956496T patent/ATE318258T1/en active
- 2000-08-29 UA UA2002032271A patent/UA72541C2/en unknown
- 2000-08-29 DK DK00956496T patent/DK1208086T3/en active
- 2000-08-29 PT PT00956496T patent/PT1208086E/en unknown
- 2000-08-29 WO PCT/EP2000/008421 patent/WO2001016106A1/en active IP Right Grant
- 2000-08-29 SI SI200030851T patent/SI1208086T1/en unknown
- 2000-08-29 EE EEP200200097A patent/EE05063B1/en not_active IP Right Cessation
- 2000-08-29 CA CA002382886A patent/CA2382886C/en not_active Expired - Fee Related
- 2000-08-29 EP EP00956496A patent/EP1208086B1/en not_active Expired - Lifetime
- 2000-08-29 ES ES00956496T patent/ES2259289T3/en not_active Expired - Lifetime
- 2000-08-29 BR BR0013648-4A patent/BR0013648A/en not_active Application Discontinuation
-
2002
- 2002-02-20 ZA ZA200201424A patent/ZA200201424B/en unknown
- 2002-02-25 IL IL148357A patent/IL148357A/en not_active IP Right Cessation
- 2002-02-26 BG BG106439A patent/BG65544B1/en unknown
- 2002-02-27 HR HR20020182A patent/HRP20020182B1/en not_active IP Right Cessation
- 2002-02-27 NO NO20020952A patent/NO322532B1/en not_active IP Right Cessation
- 2002-10-22 HK HK02107642.5A patent/HK1046277B/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2382886A1 (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
ES2620413T3 (en) | Topical anthelmintic veterinary formulations | |
KR101793707B1 (en) | Non-steroidal anti-inflammatory solution comprising diclofenac acid, lidocaine and acid stabilizer | |
US6291527B1 (en) | Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application | |
EP2387394B1 (en) | Transdermal administration of tamsulosin | |
EP0101178B1 (en) | Topical anti-inflammatory compositions | |
AR055363A1 (en) | PHARMACEUTICAL FORMULATIONS THAT INCLUDE A BETA 2- LONG-TERM AGONIST FOR ADMINISTRATION BY NEBULIZATION | |
BRPI0508933A (en) | compositions for topical delivery | |
NO175763C (en) | Process for the preparation of a pharmaceutical composition wherein DL-tryptophan, optionally in combination with fumaric acid, is used as adjuvants | |
CA2328950A1 (en) | Piperidinopyrimidine derivatives for topical application | |
HK1084582A1 (en) | Stable solid medicinal composition for oral administration | |
HU229184B1 (en) | Highly concentrated stable meloxicam solutions | |
DE60313359D1 (en) | FENOFIBRATEDIC PHARMACEUTICAL COMPOSITION AND ITS PHYSIOLOGICALLY COMPATIBLE SALTS AND DERIVATIVES | |
US9452216B2 (en) | Agent for stabilizing acetaminophen | |
WO1995000134A1 (en) | Liquid pharmaceutical composition for oral use containing 2-(4-isobutylphenyl)propionic acid | |
NO20055601L (en) | Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients | |
SK114199A3 (en) | Nimesulide gel systems for topical use | |
WO2002000166A3 (en) | New compounds useful as antibacterial agents | |
AR085273A1 (en) | PROPELLENT FREE LIQUID FORMULATION THAT INCLUDES AN ANTIMUSCARINIC DRUG | |
CA2380757A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
NO950134L (en) | Formulations for orally administered pharmaceutical agents | |
FI95348C (en) | Process for the preparation of an orally dispensable liquid composition | |
JP7186024B2 (en) | External pharmaceutical composition | |
JPH069394A (en) | External antiphlogistic sedative liquid preparation | |
KR101625926B1 (en) | Method and improved pharmceutical composition for enhancing transderaml delivery of pde-5 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |